Catalog No.
Product Name
Application
Product Information
Citations
-
Oxytocin Antagonist
(d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin serves as an oxytocin antagonist, inhibiting the effects of oxytocin on its receptor. This compound shows potential in the study of sexual behavior and related neurobiological processes. Its application in research may further elucidate the role of oxytocin in social and reproductive behaviors. -
OT Antagonist Demethyl Derivative
OT Antagonist 1 Demethyl Derivative functions as a selective antagonist of the oxytocin receptor, exhibiting a Ki value of 50 nM. This compound demonstrates significant inhibitory activity, making it suitable for research focused on oxytocin signaling pathways and its physiological roles. It can be utilized in studies investigating the modulation of social behaviors, reproductive functions, and stress responses linked to oxytocin. -
Oxytocin Receptor
Epelsiban besylate is a selective antagonist of the oxytocin receptor, offering potential in the modulation of oxytocin-related pathways. This compound has been shown to influence various biological activities, including social behavior and reproductive functions. It is primarily utilized in research exploring the effects of oxytocin signaling in neuropsychiatric disorders and other related fields. -
Oxytocin Receptor
ALS-I-41 is a potent and selective antagonist of the oxytocin receptor, which plays a crucial role in regulating social behavior and various mental disorders. This compound demonstrates significant potential for use in behavioral pharmacology studies, particularly in non-human primates. Its administration can be performed via intranasal or intramuscular routes, and its pharmacokinetics, including central nervous system penetration and metabolic rate, have been thoroughly assessed using mass spectrometry in the cerebrospinal fluid and plasma of macaque monkeys. -
Oxytocin/Vasopressin V1a-Receptor Agonist
Kalata B7 is a cyclotide that selectively targets the oxytocin and vasopressin V1a receptors as a partial agonist. Its unique cyclic structure enables it to penetrate cell membranes effectively, facilitating its biological activity. This reagent is primarily utilized in research applications focusing on the modulation of receptor signaling pathways associated with social behavior, stress responses, and cardiovascular functions. -
Oxytocin Receptor Antagonist
(d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin is an oxytocin receptor antagonist that effectively inhibits oxytocin-induced enhancement of inhibitory postsynaptic currents in CA1 pyramidal neurons. This compound is valuable for investigating the role of oxytocin in synaptic transmission and neuronal regulation. Researchers can utilize this reagent to explore its potential implications in neurobiology and associated therapeutic applications. -
Mixture Of E/Z Forms Of OT-R Antagonist 1
(E/Z)-OT-R antagonist 1 is a mixture of E and Z isomers that functions as a selective, non-peptide antagonist of the oxytocin receptor (OT-R). This compound effectively inhibits oxytocin-induced intracellular calcium activation, exhibiting an IC50 value of 8 nM. Its potent antagonistic activity makes it a valuable tool for investigating the role of oxytocin signaling in various biological processes and pathological conditions. Researchers can utilize this reagent in studies related to neurobiology, reproductive health, and stress response mechanisms. -
Oxytocin/Arginine Vasopressin Antagonist
L-364918 is a selective antagonist of oxytocin and arginine vasopressin, exhibiting Ki values of 30 nM for oxytocin, 1300 nM for AVP-V1, and 2400 nM for AVP-V2. This compound may be beneficial for research focused on preterm labor and conditions related to water balance dysregulation. Its pharmacological profile supports investigations into the role of these neuropeptides in various physiological and pathological processes. -
Oxytocin Receptor Agonist
OT-R Agonist 1 TFA is a potent oxytocin receptor agonist with an EC50 value of 0.39 nM, making it an excellent tool for investigating oxytocin signaling pathways. Additionally, this compound exhibits V1A antagonist activity with an EC50 of 2432 nM. It is primarily utilized in research related to central nervous system disorders, providing insights into neurobiology and potential therapeutic approaches. -
Oxytocin Antagonist
L-365209 is an oxytocin antagonist that selectively inhibits the binding of oxytocin to its receptors. Its primary mechanism involves blocking the physiological effects mediated by oxytocin, which is critical in processes such as social behavior, reproduction, and stress responses. This compound is valuable for research applications investigating the role of oxytocin in various physiological and pathological conditions. -
OXTR Modulator
OXTR modulator-1 is an oxytocin receptor (OXTR) modulator that selectively influences OXTR activity. This compound exhibits potential biological activity in enhancing social behavior and emotional processing, making it a valuable tool for research into neuropsychiatric disorders and social cognition. Its applications extend to studies investigating the physiological and therapeutic roles of oxytocin in various animal models. -
OXTR Modulator
OXTR modulator-2 is a selective modulator of the oxytocin receptor (OXTR), influencing pathways associated with social behavior and emotional responses. This compound enhances OXTR activity, making it instrumental in research on neuropsychiatric disorders, stress resilience, and social cognition. Its application extends to investigating the role of oxytocin in various biological processes, enabling insights into therapeutic strategies targeting mood and anxiety disorders. -
RFamide Neuropeptide
Neuropeptide AF (cattle) is an amidated octadecapeptide that targets RFamide neuropeptide receptors. It serves as a ligand for Mas-related gene receptor A4 (MrgprA4) with an EC50 of approximately 60 nM and MrgprC11 with an EC50 around 300 nM. Additionally, it activates the G protein-coupled receptors NPFF1 and NPFF2, exhibiting EC50 values ranging from 25-325 nM and 1-5 nM, respectively. Neuropeptide AF (cattle) demonstrates anti-opiate properties and plays a significant role in pain modulation research applications. -
MCHR1 Antagonist
SNAP 94847 hydrochloride is a selective antagonist targeting the melanin-concentrating hormone receptor 1 (MCHR1), exhibiting high affinity with a Ki value of 2.2 nM and Kd value of 530 pM. This compound demonstrates significant selectivity, showing over 80-fold and over 500-fold preference for MCHR1 over MCHα1A and MCHD2 receptors, respectively. SNAP 94847 hydrochloride binds effectively to MCHR1 in both mouse and rat models, displaying minimal cross-reactivity with other GPCRs, ion channels, enzymes, and transporters. Its properties make it a valuable tool for studying MCHR1-related biological processes and potential therapeutic applications. -
Melanogenesis Inhibitor
Ethyl linolenate is a fatty acid ethyl ester that functions as a melanogenesis inhibitor. It effectively reduces melanin production in cells, exhibiting an IC50 of 70 μM. This compound is valuable in research applications focused on skin pigmentation and related disorders, as well as in the exploration of potential therapeutic agents for hyperpigmentation conditions. -
MCH Receptor 1 Antagonist
BI 186908 is a selective and orally active antagonist of the melanin-concentrating hormone (MCH) receptor 1, demonstrating an IC50 of 22 nM and a Ki of 14 nM. This compound exhibits high affinity for recombinant MCH-R1 across several species, including human, cynomolgus monkey, dog, and rat, with IC50 values ranging from 18 nM to 23 nM. BI 186908 has been shown to significantly reduce body weight in diet-induced obese rat models, making it a valuable tool for research in obesity and related metabolic disorders. -
MCH1 receptor Antagonist
RGH-706 is a selective MCH1 receptor antagonist with an IC50 of 6.2 nM against human MCHR1, demonstrating oral bioavailability and the ability to cross the blood-brain barrier. This compound is primarily utilized in research focused on obesity and Prader-Willi syndrome, as it effectively improves obesity-related outcomes without antagonizing hMCH2 receptors. RGH-706 serves as a valuable tool for studying mechanisms of appetite regulation and metabolic disorders. -
MCHR-1 Antagonist
BMS-830216 is a potent antagonist of the melanin-concentrating hormone receptor 1 (MCHR-1). As a phosphate ester prodrug, it exhibits effective conversion to its active form in biological systems. This compound is primarily utilized in obesity-related research, providing insights into the role of MCHR-1 in energy homeostasis and potential therapeutic strategies for weight management. -
MCH R1 Antagonist
GW-803430 is a potent and selective antagonist of the melanin-concentrating hormone receptor 1 (MCH R1), exhibiting a pIC50 of 9.3. This compound demonstrates significant biological activity by inhibiting MCH R1, which plays a critical role in regulating energy balance and appetite. GW-803430 is primarily utilized in research applications focusing on obesity and metabolic disorders, providing insight into the therapeutic potential for weight management strategies. -
MCH1R Antagonist
ATC0175 is a potent and selective antagonist of the melanin-concentrating hormone 1 receptor (MCH1R) with an IC50 of 13.5 nM, exhibiting minimal effect on MCH2R (IC50 > 10,000 nM). This compound demonstrates significant antidepressant and anxiolytic activity in various animal models. ATC0175 serves as a valuable tool for investigating the mechanisms underlying depression and anxiety disorders in preclinical research. -
SLC-1/S643b Agonist
(Phe13,Tyr19)-MCH (human, mouse, rat) is a selective agonist for the SLC-1 and S643b receptors. This compound exhibits robust biological activity that can be utilized to investigate the signaling pathways regulated by these receptors. It is suitable for research applications in neurobiology and pharmacology, providing valuable insights into receptor function and potential therapeutic targets. -
MCH Receptor Agonist
Ac-hMCH(6-16)-NH2 is a non-selective agonist targeting the human melanin-concentrating hormone (MCH) receptors, specifically MCH-1R and MCH-2R, with IC50 values of 0.16 nM and 2.7 nM, respectively. This compound effectively activates both receptor subtypes in the brain, making it a valuable tool for studying the physiological roles of MCH signaling. Research applications include investigations into metabolic regulation, feeding behavior, and neuroendocrine function. -
Selective MCH1R Antagonist
TC-MCH 7c is a selective antagonist of the melanin-concentrating hormone receptor 1 (MCH1R), featuring a phenylpyridone structure. This compound demonstrates high potency with an IC50 of 5.6 nM for human MCH1R, alongside Kis of 3.4 nM and 3.0 nM for human and mouse MCH1R, respectively. TC-MCH 7c is designed for oral administration and effectively penetrates the brain, making it a valuable tool for research in neurological disorders and metabolic regulation. -
MCHR1 Antagonist
GW856464 is a selective antagonist of the melanin-concentrating hormone receptor 1 (MCHR1). This compound exhibits potential biological activity in the modulation of appetite and energy homeostasis, making it useful for the investigation of mechanisms underlying obesity and related metabolic disorders. Additionally, GW856464 may aid in research related to cardiovascular diseases by elucidating the role of MCHR1 in cardiovascular function. -
MCHR1 Ligand
[Ala17]-MCH is a selective ligand for the melanin-concentrating hormone receptor 1 (MCHR1), exhibiting a Ki value of 0.16 nM, indicating strong affinity compared to MCHR2, which has a Ki of 34 nM. The Eu3+ chelate-labeled form demonstrates high binding affinity for MCHR1 with a Kd of 0.37 nM, while showing negligible interaction with MCHR2. This compound is valuable for research applications involving MCHR1-mediated pathways, particularly in the study of neuropeptide signaling and metabolic regulation. -
MCHR1 Inhibitor
BMS-814580 is a selective melanocortin receptor 1 (MCHR1) inhibitor with a Ki of 16.9 nM against human MCHR1. This compound demonstrates significant antiobesity effects, making it a valuable tool for research into metabolic disorders and weight management. BMS-814580 can be utilized in studies exploring the role of MCHR1 in energy homeostasis and therapeutic approaches to obesity. -
MCHR1 Antagonist
MCHR1 antagonist 3 is a potent antagonist of the melanin-concentrating hormone receptor-1 (MCHR1). By inhibiting MCHR1 activity, this compound plays a pivotal role in the regulation of energy metabolism. It is valuable in research applications exploring metabolic disorders and the mechanisms underlying energy homeostasis. -
hMCHR1 Antagonist
hMCH-1R antagonist 1 is a selective antagonist of the human melanin-concentrating hormone receptor 1 (hMCHR1) with a binding affinity characterized by a KB value of 3.6 nM. This compound demonstrates effective inhibition of hMCHR1 and hMCHR2, with IC50 values of 65 nM and 49 nM, respectively. hMCH-1R antagonist 1 is suitable for investigations into metabolic pathways and the role of melanin-concentrating hormone in various physiological processes. -
MCH-R1 Antagonist
ATC0175 free base is a potent and selective antagonist of the melanin-concentrating hormone receptor 1 (MCH-R1), exhibiting an IC50 value of 3.4 nM. This compound demonstrates strong selectivity over Y5 and α2A receptors, making it an important tool for investigations in obesity research. Its mechanism of action provides valuable insights into metabolic regulation and potential therapeutic strategies for related conditions. -
MCH-R Ligand
MCH (human, mouse, rat) is a cyclic neuropeptide that functions as an endogenous ligand for the melanin-concentrating hormone receptor (MCH-R). It exhibits high binding affinity with IC50 values of 0.3 nM and 1.5 nM for human MCH-1R and MCH-2R, respectively, and operational EC50 values of 3.9 nM and 88.7 nM. MCH plays a crucial role in regulating appetite as an orexigenic signal and is instrumental in maintaining energy homeostasis and sleep-wake cycles. This reagent is essential for research into obesity, sleep-related disorders, and related metabolic conditions. -
MCHR1 Antagonist/Anti-Obesity Agent
MCHR1 Antagonist 4 is a potent antagonist targeting the Melanin-Concentrating Hormone Receptor 1 (MCHR1), demonstrating Ki values of 0.74 nM for human MCHR1 and 0.76 nM for rat MCHR1. This compound effectively penetrates the blood-brain barrier, making it a valuable tool in research related to obesity and metabolic disorders. Its role as an anti-obesity agent positions it as a significant candidate for studies focused on weight management and appetite regulation. -
MCHR1 Antagonist
AMG-076 free base is a selective antagonist of the Melanin-Concentrating Hormone Receptor 1 (MCHR1). It has been shown to significantly reduce body weight gain in non-obese mice subjected to a high-fat diet, as well as in diet-induced obese (DIO) mice. This compound is valuable for research into obesity and metabolic disorders, providing insights into the therapeutic potential of targeting MCHR1 in weight management. -
MCHR1 Antagonist
AMG-076 is a selective antagonist of the melanin-concentrating hormone receptor-1 (MCHR1). This compound has demonstrated significant reductions in body weight gain in both nonobese mice on a high-fat diet and in diet-induced obese (DIO) mice. AMG-076 serves as a valuable tool for studying obesity and metabolic disorders in preclinical research. -
Melanin-concentrating Hormone Receptor Antagonist
T-226296 is a selective antagonist of the melanin-concentrating hormone receptor, exhibiting IC50 values of 5.5 nM and 8.6 nM for human and rat SLC-1, respectively. This compound demonstrates potential in modulating weight and metabolic processes, making it useful in research on obesity and insulin resistance. Its oral bioavailability facilitates in vivo studies, providing insights into the role of melanin-concentrating hormone signaling in metabolic disorders. -
a-melanocyte Stimulating Hormone Analog
Modimelanotide is an α-melanocyte-stimulating hormone analog that exhibits high specificity for melanocortin receptors MCR1, MCR3, MCR4, and MCR5. This compound demonstrates notable anti-inflammatory and organ-protective properties, making it a valuable tool for research in conditions such as acute kidney injury. Investigating Modimelanotide can enhance understanding of melanocortin receptor signaling and its implications in various disease contexts. -
Melanogenesis Inhibitory Agent
Cadin-1(14)-ene-7a,11-diol is a sesquiterpene alcohol that functions as a melanogenesis inhibitory agent. It effectively suppresses melanin production in B16 melanoma cells stimulated by α-MSH, demonstrating potential application in skin-whitening treatments. This compound is valuable for research exploring mechanisms of pigmentation and therapies for hyperpigmentation disorders. -
MC4R Antagonist
TCMCB07 is a cyclic nonapeptide that functions as an antagonist of the melanocortin receptor 4 (MC4R). This compound demonstrates significant potential in the study of cachexia, exhibiting oral bioavailability and the ability to penetrate the blood-brain barrier. Its unique structure may also confer additional transport capabilities, making it a valuable tool in related research applications. -
MC-1 Receptor Agonist
BMS-470539 dihydrochloride is a selective agonist of the melanocortin-1 receptor (MC-1R), exhibiting an IC50 of 120 nM and an EC50 of 28 nM. This compound demonstrates potent anti-inflammatory properties while showing no activation of MC-3R and minimal partial agonism at MC-4R and MC-5R. BMS-470539 dihydrochloride is utilized in research focused on inflammatory conditions and the modulation of skin pigmentation. -
MC1R Agonist
Dersimelagon is a selective agonist of the melanocortin 1 receptor (MC1R) with demonstrated efficacy in human (EC50 of 8.16 nM), cynomolgus monkey (3.91 nM), mouse (1.14 nM), and rat (0.251 nM) models. It exhibits strong binding affinity for hMC1R and hMC4R, with Ki values of 2.26 nM and 32.9 nM, respectively. This compound is primarily utilized in research focused on skin pigmentation and the modulation of melanin synthesis. -
MC4R Agonist
Bivamelagon is a selective agonist of the melanocortin 4 receptor (MC4R) with an EC50 of 0.562 nM in a luciferase assay and 36.5 nM in a cAMP assay, demonstrating its potent activity. This compound exhibits a Ki value of 65 nM, indicating strong binding affinity to its target. Bivamelagon is valuable for research into metabolic disorders, particularly in the context of obesity and diabetes, providing insights into potential therapeutic applications. -
MC1R Antagonist
MSG606 is a selective antagonist of the melanocortin 1 receptor (MC1R), known for its ability to negate the neuroprotective effects of MC1R agonists. This compound effectively inhibits cancer cell proliferation and disrupts the transition from the G1 to S phase of the cell cycle. Additionally, MSG606 has demonstrated potential in delaying pain hypersensitivity and reducing cholesterol levels. It is valuable for research applications related to cancer, inflammation, neurological disorders, and metabolic diseases, including breast cancer and subarachnoid hemorrhage. -
Melanocortin Receptor Agonist
Adrenocorticotropic Hormone (ACTH) (1-39), human is a potent melanocortin receptor agonist. It plays a critical role in stimulating cortisol release from the adrenal cortex and is involved in regulating stress responses, metabolism, and immune function. This peptide can be utilized in research focusing on adrenal function, neuroendocrine regulation, and related therapeutic studies. -
MC4R Agonist
α-MSH TFA is a potent agonist of the melanocortin receptor 4 (MC4R). This endogenous neuropeptide exhibits anti-inflammatory and antipyretic properties, making it valuable for research into metabolic regulation and neuroinflammatory responses. As a post-translational derivative of pro-opiomelanocortin (POMC), α-MSH TFA serves as an important tool for studying the physiological roles of melanocortins in various biological processes. -
MC4R Agonist
MK-0493 is an orally active agonist of the melanocortin-4 receptor (MC4R), known for its role in regulating appetite and energy balance. This compound is demonstrated to reduce food intake and suppress weight gain, while also elevating blood pressure at elevated doses. Additionally, MK-0493 displays preclinical activity in erectile function regulation, making it a valuable tool in obesity and metabolic disorder research. -
Melanocortin Receptor Agonist
Adrenocorticotropic hormone (1-39), rat is a potent agonist of the melanocortin 2 (MC2) receptor. This peptide is crucial in regulating adrenal steroidogenesis and is significant for research in stress response and metabolism. Its use in studies can provide valuable insights into the functioning of the hypothalamic-pituitary-adrenal (HPA) axis and related endocrine disorders. -
MC4-R Agonist
β-Melanocyte Stimulating Hormone (MSH), human, is a 22-residue peptide that functions as an endogenous agonist of the melanocortin-4 receptor (MC4-R). It plays a critical role in regulating energy homeostasis, appetite, and body weight. This compound is valuable for research applications focused on metabolic disorders, obesity, and neurobiology. -
Melanocortin Receptor Agonist
Bremelanotide is a potent melanocortin receptor agonist that primarily targets the MC4R. It is known to enhance dopamine release, leading to the modulation of appetitive sexual behaviors, including female mounting behavior and repetitive self-grooming. This compound is valuable for investigating hypoactive sexual desire disorders and understanding the neurobiological mechanisms underlying sexual arousal and motivation. -
Melanocortin Receptor Antagonist
SNT-207858 free base is a selective melanocortin-4 (MC-4) receptor antagonist that effectively penetrates the blood-brain barrier. With an IC50 of 22 nM for binding and 11 nM for functional inhibition, this compound demonstrates potent activity against the MC-4 receptor. It is a valuable tool for research applications focused on understanding melanocortin signaling pathways and their implications in neurological and metabolic disorders. -
MC4 Antagonist
PF-07258669 is a potent orally active antagonist of the melanocortin-4 receptor (MC4R), displaying an IC50 of 13 nM and a Ki of 0.46 nM. This compound has significant implications for research into conditions related to cachexia, anorexia, and anorexia nervosa, making it a valuable tool for studying the regulatory mechanisms of appetite and energy homeostasis. -
MC4R Antagonist
ML-00253764 hydrochloride is a nonpeptidic antagonist of the melanocortin receptor 4 (MC4R), demonstrating a Ki of 0.16 μM and an IC50 of 0.103 μM. This compound effectively penetrates the blood-brain barrier, making it suitable for central nervous system studies. Its antagonistic activity at MC4R suggests potential applications in obesity research and metabolic disorder investigations.
